A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

November 1, 2027

Study Completion Date

November 30, 2027

Conditions
Relapsed or Refractory Acute Myeloid Leukemia
Interventions
PROCEDURE

Salvage Allogeneic Hematopoietic Stem Cell Transplantation

"1. TBI+BUMEL (IBM) Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally, Day -7; Day -6: Total Body Irradiation (TBI) 4Gy, in two parts, Day -6; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion~2. Donor Stem Cell Infusion (Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg)."

Trial Locations (1)

215006

RECRUITING

Hematology Department, The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER